AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Sep 11, 2014

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease

COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. These data were presented at the 44th Annual European Society for Dermatological Research (ESDR) Meeting in Copenhagen, Denmark.3

Sep 05, 2014

AbbVie to Present at Morgan Stanley Global Healthcare Conference

NORTH CHICAGO, Ill., Sept. 5, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. Central time.

Sep 03, 2014

Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL.

Sep 03, 2014

AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.

Aug 18, 2014

AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards

NORTH CHICAGO, Ill., Aug. 18, 2014 /PRNewswire/ --  AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholarship program. Voting for two of the 40 winners to earn the title of 2014 Thriving Undergraduate or Graduate Scholar is now open to the public at www.AbbVieCFScholarship.com until September 15. 

Aug 04, 2014

AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme

NORTH CHICAGO, Ill., Aug. 4, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme.1 Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor. Each year in the U.S. and Europe, two to three out of every 100,000 people are diagnosed with glioblastoma multiforme, which has a five year survival rate of approximately four percent.2

Aug 01, 2014

AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program

NORTH CHICAGO, Ill. and PALO ALTO, Calif., Aug. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional habits in the cystic fibrosis (CF) community through the CFChef Shares program. CFChef Shares will run from August 1 to September 15, 2014, as part of AbbVie's CFChef program – an online resource for CF patients and caregivers – to encourage patients to maintain a healthy diet by submitting recipes to the Chef4CF.com Online Cookbook. The program will begin at the CFRI 27th National Family Cystic Fibrosis Education Conference, on August 1-3, 2014, in Redwood City, Calif.

Jul 16, 2014

AbbVie Announces Inaugural Week of Possibilities Volunteer Program to Support Six Schools in North Chicago, Ill., and Worcester, Mass.

NORTH CHICAGO, Ill., July 16, 2014 /PRNewswire/ -- AbbVie today announced its first Week of Possibilities, an employee volunteer program to support educational improvement projects in local communities where AbbVie is based. As part of the inaugural program, more than 1,300 AbbVie employees are donating time to help improve six elementary and middle schools in North Chicago, Ill., and Worcester, Mass. During the week of July 14-18, Week of Possibilities volunteers will transform library and learning centers, refresh classrooms and teachers' lounges, and transform an elementary school into a facility for at-risk young adults in North Chicago, where AbbVie is headquartered, and in Worcester, where its biologics research and development (R&D) center is located.